Literature DB >> 31345582

An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease.

Monique E Cho1, Jared L Hansen2, Celena B Peters2, Alfred K Cheung3, Tom Greene4, Brian C Sauer5.   

Abstract

Iron parameters have not been well characterized in pre-dialysis patients with chronic kidney disease (CKD), and it remains unclear if abnormal iron balance is associated with increased mortality. Therefore, we performed a historical cohort study using data from the Veterans Affairs Corporate Data Warehouse to evaluate the relationship between iron status and mortality. We identified a pre-dialysis CKD cohort with at least one set of iron indices between 2006-2015. The cohort was divided into four iron groups based on the joint quartiles of serum transferrin saturation (percent) and ferritin concentration (ng/ml): reference (16-28%, 55-205 ng/ml), low iron (0.4-16%, 0.4-55 ng/ml), high iron (28-99.6%, 205-4941 ng/ml), and function iron deficiency (0.8-16%, 109-2783 ng/ml). We compared mortality risk between the iron groups using matching weights based on multinomial propensity score models and Poisson rate-based regression. We also evaluated if the association between iron groups and mortality differs between the diabetic and non-diabetic subgroups. Of the 80,067 eligible veterans, 32,489 were successfully matched. During the mean follow-up period of 4.0 years, adjusted relative rate (95% confidence interval) for all-cause mortality in three abnormal iron groups were increased compared to the reference: functional iron deficiency [1.21 (1.17, 1.25)], low iron [1.10 (1.07, 1.14)], and high iron [1.09 (1.06, 1.13)]. The mortality risk was similar between diabetic and non-diabetic subgroups for each iron group. Thus, an abnormal iron balance, particularly functional iron deficiency, is associated with increased mortality in CKD.
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CKD; anemia; iron; mortality

Year:  2019        PMID: 31345582     DOI: 10.1016/j.kint.2019.04.029

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  Association of Abnormal Iron Status with the Occurrence and Prognosis of Peritoneal Dialysis-Related Peritonitis: A Longitudinal Data-Based 10-Year Retrospective Study.

Authors:  Xiangwen Diao; Zhiwei Zheng; Chunyan Yi; Peiyi Cao; Hongjian Ye; Ruihua Liu; Jianxiong Lin; Wei Chen; Haiping Mao; Fengxian Huang; Xiao Yang
Journal:  Nutrients       Date:  2022-04-13       Impact factor: 6.706

Review 2.  Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders.

Authors:  Yang Xu; Víctor M Alfaro-Magallanes; Jodie L Babitt
Journal:  Br J Haematol       Date:  2020-12-14       Impact factor: 8.615

Review 3.  Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.

Authors:  Jose Portolés; Leyre Martín; José Jesús Broseta; Aleix Cases
Journal:  Front Med (Lausanne)       Date:  2021-03-26

4.  Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases.

Authors:  Patrice Cacoub; Gabriel Choukroun; Alain Cohen-Solal; Elisabeth Luporsi; Laurent Peyrin-Biroulet; Katell Peoc'h; Valérie Andrieu; Sigismond Lasocki; Hervé Puy; Jean-Noël Trochu
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

5.  The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-Word Evidence Study among the Italian Population.

Authors:  Valentina Perrone; Chiara Veronesi; Melania Dovizio; Domenica Daniela Ancona; Fausto Bartolini; Fulvio Ferrante; Alessandro Lupi; Stefano Palcic; Davide Re; Annamaria Pia Terlizzi; Antonio Ramirez de Arellano Serna; Paolo Cogliati; Luca Degli Esposti
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

6.  Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease.

Authors:  Rupal C Mehta; Monique E Cho; Xuan Cai; Jungwha Lee; Jing Chen; Jiang He; John Flack; Tariq Shafi; Santosh L Saraf; Valentin David; Harold I Feldman; Tamara Isakova; Myles Wolf
Journal:  Kidney Int       Date:  2021-07-30       Impact factor: 10.612

Review 7.  Intravenous iron therapy and the cardiovascular system: risks and benefits.

Authors:  Lucia Del Vecchio; Robert Ekart; Charles J Ferro; Jolanta Malyszko; Patrick B Mark; Alberto Ortiz; Pantelis Sarafidis; Jose M Valdivielso; Francesca Mallamaci
Journal:  Clin Kidney J       Date:  2020-11-26

8.  Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia.

Authors:  Murilo Guedes; Daniel G Muenz; Jarcy Zee; Brian Bieber; Benedicte Stengel; Ziad A Massy; Nicolas Mansencal; Michelle M Y Wong; David M Charytan; Helmut Reichel; Sandra Waechter; Ronald L Pisoni; Bruce M Robinson; Roberto Pecoits-Filho
Journal:  J Am Soc Nephrol       Date:  2021-07-08       Impact factor: 14.978

9.  Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis.

Authors:  Hirokazu Honda; Miho Kimachi; Noriaki Kurita; Nobuhiko Joki; Masaomi Nangaku
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

10.  Serum transferrin predicts end-stage Renal Disease in Type 2 Diabetes Mellitus patients.

Authors:  Lijun Zhao; Yutong Zou; Junlin Zhang; Rui Zhang; Honghong Ren; Lin Li; Ruikun Guo; Jie Zhang; Fang Liu
Journal:  Int J Med Sci       Date:  2020-07-29       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.